| Literature DB >> 31632937 |
Jianli Lv1, Bo Han1, Cuiyan Wang2, Jing Wang1, Diandong Jiang1, Lijian Zhao1, Yingchun Yi1, Jianjun Zhang1.
Abstract
Objective: To investigate the clinical features and the diagnostic and follow-up value of acute fulminant myocarditis (AFM) in children.Entities:
Keywords: ECMO; acute fulminant myocarditis; cardiovascular magnetic resonance; children; pacemaker
Year: 2019 PMID: 31632937 PMCID: PMC6779687 DOI: 10.3389/fped.2019.00388
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Main clinical data of 20 children with AFM.
| 1 | 9 | F | Abdominal pain, vomiting | ASO | 2,102 | – | Yes | 25 | 7 | – | + | Yes | – | 34 |
| 2 | 6 | M | Vomiting | MP | 1,632 | CAVB | Yes | 40 | 11 | + | + | Yes | – | 28 |
| 3 | 13 | M | Syncope | – | 1,967 | CAVB | Yes | 38 | 12 | + | + | Yes | Pacemaker | 33 |
| 4 | 7 | M | Abdominal pain | – | 2,783 | CAVB | Yes | 60 | 17 | – | – | Yes | Pacemaker | 16 |
| 5 | 8 | F | Abdominal pain, vomiting | MP | 6,457 | – | Yes | 33 | 13 | + | + | Yes | – | 29 |
| 6 | 10 | F | Abdominal pain | ASO | 269.2 | – | Yes | 30 | 24 | – | – | Yes | – | 32 |
| 7 | 12 | F | Abdominal pain | – | 1,791 | CAVB | Yes | 42 | 13 | – | – | Yes | – | 25 |
| 8 | 3 | M | Abdominal pain, vomiting | – | 1,864 | AAVB | Yes | 48 | 12 | + | + | Yes | – | 24 |
| 9 | 8 | M | Convulsion | MP | 956 | CAVB | No | 41 | 17 | + | + | No | Pacemaker | 22 |
| 10 | 16 | F | Chest tightness | EBV | 3,367 | – | No | 43 | 11 | + | + | Yes | – | 28 |
| 11 | 10 | M | Fatigue | HHV6 | 1,550 | CAVB | No | 61 | 69 | – | – | Yes | Pacemaker | 34 |
| 12 | 9 | M | Vomiting | MP | 822.3 | – | Yes | 38 | 6 | + | – | No | – | 13 |
| 13 | 7 | M | Palpitation | EBV, HHV6 | 212 | – | Yes | 37 | 20 | + | + | No | – | 26 |
| 14 | 5 | M | Vomiting | MP | 1,011 | AAVB | Yes | 50 | 12 | - | + | No | – | 19 |
| 15 | 10 | F | Fatigue | – | 1,164 | – | Yes | 35 | 10 | + | + | No | – | 22 |
| 16 | 9 | F | Syncope | MP | 1,477 | CAVB | No | 62 | 10 | + | + | No | Pacemaker | 23 |
| 17 | 7 | F | Vomiting | ASO | 1,105 | CAVB | Yes | 39 | 16 | + | + | No | Pacemaker | 19 |
| 18 | 3 | M | Fatigue | – | 1,188 | CAVB | Yes | 37 | 11 | + | + | No | Pacemaker | 31 |
| 19 | 7 | M | Abdominal pain, vomiting | – | 7,605 | VT | Yes | 20 | 23 | + | + | Yes | ECMO | 26 |
| 20 | 9 | M | Vomiting | – | 2,187 | CAVB | No | 45 | 38 | – | + | No | Pacemaker | 42 |
hs-cTnT, hypersensitive cardiac troponin T; CCE, cardiac chamber enlargement; LVEF, left ventricular ejection fraction; FIT, first inspection time; UOG, use of glucocorticoid; MCS, mechanical circulation support; LOS, length of stay; ASO, anti-streptolysin O; MP, mycoplasma pneumonia; EBV, Epstein-Barr virus; HHV6, human herpesvirus 6; CAVB, complete atrioventricular block; AAVB, advanced atrioventricular block; VT, ventricular tachycardia.
Figure 1The trend of hs-cTnT (A) and NT-pro BNP (B) with the course of disease.
Comparison of the hs-cTnT peak and the length of stay between the glucocorticoid group and the unused glucocorticoid group.
| hs-cTnT peak (pg/ml) | 2853.4 ± 2217.2 | 1124.7 ± 527.3 | <0.05 |
| Time of hs-cTnT to normal (days) | 21.6 ± 5.9 | 22.0 ± 5.7 | >0.05 |
| Time of LVEF to normal (days) | 16.9 ± 5.2 | 27.3 ± 25.0 ( | >0.05 |
| Length of stay(days) | 28.1 ± 5.4 | 24.1 ± 8.3 | >0.05 |